Market Pathways
By Market Pathways
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Market Pathways
Category: Business
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 30
Description
Your premium guide to global medical device regulation, reimbursement and policy. Market Pathways delivers incomparable intelligence exploring the people, challenges, and opportunities impacting the global medtech regulatory and reimbursement community. View the latest issue of Market Pathways on MyStrategist.com
| Episode | Date |
|---|---|
|
BTIG Weighs In on Whether Trump Policies Can Dent MedTech’s Healthy Run
|
Mar 07, 2025 |
|
Pioneering the Use of Real-World Evidence in Medtech: A Discussion with J&J’s Paul Coplan
|
Aug 01, 2024 |
|
FDA Inspections Getting Prepped and Avoiding Pitfalls
|
May 25, 2024 |
|
A VC’s View of the Reimbursement Evolution: An Interview with Mike Carusi
|
Mar 27, 2024 |
|
Reimbursement for Breakthrough Devices Still Lags—Need for TCET: An Interview with Josh Makower
|
Sep 19, 2023 |
|
Ep. 25: Medtech in China: An Island of Relative Calm in a Sea of Volatility
|
Aug 10, 2023 |
|
An Interview With Kevin Fu, The First Device Cyber Czar
|
Jun 27, 2023 |
|
The Real World Impact of MDR: How CEOs and Investors are Adapting
|
May 19, 2023 |
|
Medtech Law & Policy - Clearing Up the Confusion on MDR: Where Do We Go From Here?
|
Feb 09, 2023 |
|
What Do the US Midterms Mean for Medtech?
|
Dec 01, 2022 |
|
What in the (Medtech) World is Happening?
|
Sep 22, 2022 |
|
Tracking the Changing Reimbursement Landscape
|
Aug 18, 2022 |
|
Changes in China Present New Opportunities
|
Jul 19, 2022 |
|
MDR is Here - Now What Does That Mean?
|
Jun 16, 2022 |
|
Sandra Siami on the Promise and Challenges of Real World Evidence
|
May 26, 2022 |
|
Do We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan
|
May 13, 2022 |
|
The Medical Imaging Perspective with Patrick Hope
|
Apr 14, 2022 |
|
Looking Ahead in MedTech Policy: Part 2
|
Mar 03, 2022 |
|
Looking Ahead in MedTech Policy: Part 1
|
Feb 22, 2022 |
|
Bringing the Value of Medtech Regulatory, Reimbursement and Policy Issues to Innovators Through Data: A Conversation with Stanford Biodesign’s Josh Makower
|
Feb 05, 2022 |
|
Bridging the Regulatory-Reimbursement Gap: Opportunities and Challenges
|
Jan 20, 2022 |
|
AdvaMed’s Scott Whitaker on Partnering and Advocacy
|
Dec 02, 2021 |
|
FDA and Digital Medtech
|
Nov 18, 2021 |
|
FDA's Revival of US Early Feasibility Studies; Can Industry Keep Up?
|
Oct 07, 2021 |
|
Appraising the Medtech Innovation Ecosystem with Nadim Yared
|
Sep 23, 2021 |
|
A Look Ahead at the Coming Medtech “School Year”: A Conversation with MDMA’s Mark Leahey
|
Sep 09, 2021 |
|
New Chinese Medtech Regulations Offer New Opportunities
|
Aug 12, 2021 |
|
The Role of Health Tech Assessments in EU/UK Reimbursement
|
Jul 28, 2021 |
|
Jeff Shuren on FDA-sponsor interactions: Where they’ve been and where they’re going
|
Jul 15, 2021 |
|
MDR is Here – Now What?” featuring Serge Bernasconi, CEO of Medtech Europe
|
Jul 01, 2021 |